Transdermal estradiol in castrate and chemotherapy resistant prostate cancer.

Date publication

avril 2012

Journal

Medical science monitor : international medical journal of experimental and clinical research

Auteurs

Membres identifiés du Cancéropôle Est :
Dr METZGER Daniel

Tous les auteurs :
Stein M, Goodin S, Doyle-Lindrud S, Silberberg J, Kane M, Metzger D, Eddy S, Shih W, DiPaola RS

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/22460098

Résumé

Given prior studies demonstrating the marked clinical activity of oral estrogens in prostate cancer, more recent data demonstrating the safety of transdermal estradiol, and the renewed interest in targeting testosterone metabolism and androgen receptor pathways, we report the results of a trial of transdermal estradiol in advanced heavily pre-treated castrate and chemotherapy refractory patients.

Mots clés

Administration, Cutaneous, Aged, Aged, 80 and over, Castration, Demography, Drug Resistance, Neoplasm, Estradiol, administration & dosage, Humans, Male, Middle Aged, Prostatic Neoplasms, blood, Testosterone, blood

Référence

Med. Sci. Monit.. 2012 Apr;18(4):CR260-4